Show simple item record

dc.contributor.authorDomi, A.
dc.contributor.authorFeldmann, F.
dc.contributor.authorBasu, R.
dc.date.accessioned2019-06-21T18:46:24Z
dc.date.available2019-06-21T18:46:24Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85040942560&doi=10.1038%2fs41598-017-19041-y&partnerID=40&md5=3fc63631373b530663ed461ddec76976
dc.identifier.urihttp://hdl.handle.net/10713/9667
dc.description.abstractEbola virus (EBOV), isolate Makona, was the causative agent of the West African epidemic devastating predominantly Guinea, Liberia and Sierra Leone from 2013-2016. While several experimental vaccine and treatment approaches have been accelerated through human clinical trials, there is still no approved countermeasure available against this disease. Here, we report the construction and preclinical efficacy testing of a novel recombinant modified vaccinia Ankara (MVA)-based vaccine expressing the EBOV-Makona glycoprotein GP and matrix protein VP40 (MVA-EBOV). GP and VP40 form EBOV-like particles and elicit protective immune responses. In this study, we report 100% protection against lethal EBOV infection in Guinea pigs after prime/boost vaccination with MVA-EBOV. Furthermore, this MVA-EBOV protected macaques from lethal disease after a single dose or prime/boost vaccination. The vaccine elicited a variety of antibody responses to both antigens, including neutralizing antibodies and antibodies with antibody-dependent cellular cytotoxic activity specific for GP. This is the first report that a replication-deficient MVA vector can confer full protection against lethal EBOV challenge after a single dose vaccination in macaques. Copyright 2018 The Author(s).en_US
dc.description.urihttps://dx.doi.org/10.1038/s41598-017-19041-yen_US
dc.language.isoen-USen_US
dc.publisherNature Publishing Groupen_US
dc.relation.ispartofScientific Reports
dc.subject.meshEbola Vaccinesen_US
dc.subject.meshHemorrhagic Fever, Ebola--prevention & controlen_US
dc.titleA Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challengeen_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41598-017-19041-y
dc.identifier.pmid29339750


This item appears in the following Collection(s)

Show simple item record